441 related articles for article (PubMed ID: 29191972)
1. Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study.
Norquist BM; Brady MF; Harrell MI; Walsh T; Lee MK; Gulsuner S; Bernards SS; Casadei S; Burger RA; Tewari KS; Backes F; Mannel RS; Glaser G; Bailey C; Rubin S; Soper J; Lankes HA; Ramirez NC; King MC; Birrer MJ; Swisher EM
Clin Cancer Res; 2018 Feb; 24(4):777-783. PubMed ID: 29191972
[No Abstract] [Full Text] [Related]
2. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
Tewari KS; Burger RA; Enserro D; Norquist BM; Swisher EM; Brady MF; Bookman MA; Fleming GF; Huang H; Homesley HD; Fowler JM; Greer BE; Boente M; Liang SX; Ye C; Bais C; Randall LM; Chan JK; Ferriss JS; Coleman RL; Aghajanian C; Herzog TJ; DiSaia PJ; Copeland LJ; Mannel RS; Birrer MJ; Monk BJ
J Clin Oncol; 2019 Sep; 37(26):2317-2328. PubMed ID: 31216226
[TBL] [Abstract][Full Text] [Related]
3. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
Swisher EM; Aghajanian C; O'Malley DM; Fleming GF; Kaufmann SH; Levine DA; Birrer MJ; Moore KN; Spirtos NM; Shahin MS; Reid TJ; Friedlander M; Steffensen KD; Okamoto A; Sehgal V; Ansell PJ; Dinh MH; Bookman MA; Coleman RL
Gynecol Oncol; 2022 Feb; 164(2):245-253. PubMed ID: 34906376
[TBL] [Abstract][Full Text] [Related]
4. Clonal tumor mutations in homologous recombination genes predict favorable clinical outcome in ovarian cancer treated with platinum-based chemotherapy.
Luo S; Zhang Y; Yang Y; Zhu S; Liu W; Zhu J; Liang X; Jiang Z; Sun S; Hou X; Xiao Y; Li X
Gynecol Oncol; 2020 Jul; 158(1):66-76. PubMed ID: 32402633
[TBL] [Abstract][Full Text] [Related]
5. Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
Gillen J; Miller A; Bell-McGuinn KM; Schilder RJ; Walker JL; Mathews CA; Duska LR; Guntupalli SR; O'Cearbhaill R; Hays J; Hagemann AR; Gray HJ; Gordon SW; Armstrong DK; Chen A; Fracasso PM; Aghajanian C; Moore KN
Gynecol Oncol; 2021 May; 161(2):512-515. PubMed ID: 33610319
[TBL] [Abstract][Full Text] [Related]
6. Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.
Alvarez Secord A; Bell Burdett K; Owzar K; Tritchler D; Sibley AB; Liu Y; Starr MD; Brady JC; Lankes HA; Hurwitz HI; Mannel RS; Tewari KS; O'Malley DM; Gray H; Bakkum-Gamez JN; Fujiwara K; Boente M; Deng W; Burger RA; Birrer MJ; Nixon AB
Clin Cancer Res; 2020 Mar; 26(6):1288-1296. PubMed ID: 31919136
[TBL] [Abstract][Full Text] [Related]
7.
Mirza MR; Lindahl G; Mahner S; Redondo A; Fabbro M; Rimel BJ; Herrstedt J; Oza AM; Canzler U; Berek JS; González-Martín A; Follana P; Lord R; Azodi M; Estenson K; Wang Z; Li Y; Gupta D; Matulonis U; Feng B
Cancer Res Commun; 2022 Nov; 2(11):1436-1444. PubMed ID: 36970052
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
Oliver KE; Brady WE; Birrer M; Gershenson DM; Fleming G; Copeland LJ; Tewari K; Argenta PA; Mannel RS; Secord AA; Stephan JM; Mutch DG; Stehman FB; Muggia FM; Rose PG; Armstrong DK; Bookman MA; Burger RA; Farley JH
Gynecol Oncol; 2017 Nov; 147(2):243-249. PubMed ID: 28807367
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.
Jean S; Li J; Katsaros D; Wubbenhorst B; Maxwell KN; Fishbein L; McLane MW; Benedetto C; Canuto EM; Mitra N; Zhang L; Nathanson KL; Tanyi JL
Oncotarget; 2016 Jul; 7(30):48577-48585. PubMed ID: 27191893
[TBL] [Abstract][Full Text] [Related]
10. Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.
Pujade-Lauraine E; Brown J; Barnicle A; Wessen J; Lao-Sirieix P; Criscione SW; du Bois A; Lorusso D; Romero I; Petru E; Yoshida H; Vergote I; Colombo N; Hietanen S; Provansal M; Schmalfeldt B; Pignata S; Martín Lorente C; Berton D; Runnebaum IB; Ray-Coquard I
JCO Precis Oncol; 2023 Jan; 7():e2200258. PubMed ID: 36716415
[TBL] [Abstract][Full Text] [Related]
11. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.
Leslie KK; Filiaci VL; Mallen AR; Thiel KW; Devor EJ; Moxley K; Richardson D; Mutch D; Secord AA; Tewari KS; McDonald ME; Mathews C; Cosgrove C; Dewdney S; Casablanca Y; Jackson A; Rose PG; Zhou X; McHale M; Lankes H; Levine DA; Aghajanian C
Gynecol Oncol; 2021 Apr; 161(1):113-121. PubMed ID: 33541735
[TBL] [Abstract][Full Text] [Related]
12. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Oza AM; Cook AD; Pfisterer J; Embleton A; Ledermann JA; Pujade-Lauraine E; Kristensen G; Carey MS; Beale P; Cervantes A; Park-Simon TW; Rustin G; Joly F; Mirza MR; Plante M; Quinn M; Poveda A; Jayson GC; Stark D; Swart AM; Farrelly L; Kaplan R; Parmar MK; Perren TJ;
Lancet Oncol; 2015 Aug; 16(8):928-36. PubMed ID: 26115797
[TBL] [Abstract][Full Text] [Related]
13. Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study.
Tewari KS; Java JJ; Eskander RN; Monk BJ; Burger RA
Ann Oncol; 2016 Jan; 27(1):114-21. PubMed ID: 26487588
[TBL] [Abstract][Full Text] [Related]
14. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.
Ferriss JS; Java JJ; Bookman MA; Fleming GF; Monk BJ; Walker JL; Homesley HD; Fowler J; Greer BE; Boente MP; Burger RA
Gynecol Oncol; 2015 Oct; 139(1):17-22. PubMed ID: 26216729
[TBL] [Abstract][Full Text] [Related]
15. Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.
Tian C; Ambrosone CB; Darcy KM; Krivak TC; Armstrong DK; Bookman MA; Davis W; Zhao H; Moysich K; Gallion H; DeLoia JA
Gynecol Oncol; 2012 Mar; 124(3):575-81. PubMed ID: 22112610
[TBL] [Abstract][Full Text] [Related]
16. An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.
Gore M; Hackshaw A; Brady WE; Penson RT; Zaino R; McCluggage WG; Ganesan R; Wilkinson N; Perren T; Montes A; Summers J; Lord R; Dark G; Rustin G; Mackean M; Reed N; Kehoe S; Frumovitz M; Christensen H; Feeney A; Ledermann J; Gershenson DM
Gynecol Oncol; 2019 Jun; 153(3):541-548. PubMed ID: 31005287
[TBL] [Abstract][Full Text] [Related]
17. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
duPont NC; Enserro D; Brady MF; Moxley K; Walker JL; Cosgrove C; Bixel K; Tewari KS; Thaker P; Wahner Hendrickson AE; Rubin S; Fujiwara K; Casey AC; Soper J; Burger RA; Monk BJ
Gynecol Oncol; 2022 Feb; 164(2):398-405. PubMed ID: 34857397
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.
Trillsch F; Mahner S; Hilpert F; Davies L; García-Martínez E; Kristensen G; Savarese A; Vuylsteke P; Los M; Zagouri F; Gladieff L; Sehouli J; Khoon Lee C; Gebski V; Pujade-Lauraine E
Ann Oncol; 2016 Sep; 27(9):1733-9. PubMed ID: 27287207
[TBL] [Abstract][Full Text] [Related]
20. Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer.
Ramalingam SS; Blais N; Mazieres J; Reck M; Jones CM; Juhasz E; Urban L; Orlov S; Barlesi F; Kio E; Keiholz U; Qin Q; Qian J; Nickner C; Dziubinski J; Xiong H; Ansell P; McKee M; Giranda V; Gorbunova V
Clin Cancer Res; 2017 Apr; 23(8):1937-1944. PubMed ID: 27803064
[No Abstract] [Full Text] [Related]
[Next] [New Search]